Pharmaceuticals & Therapeutics

The new iPSC-derived sensory neurons offer a reproducible human model, aiming to fix the broken pipeline of pain research and accelerate new analgesics.

A new, smaller implant for back surgery promises easier procedures for surgeons and lasting relief for patients by tackling the risk of reherniation.

Cordis presents pivotal 12-month data for its innovative SELUTION SLR drug-eluting balloon, a device that could change how doctors treat clogged arteries.

In a booming aesthetics market, one company is enlisting elite surgeons to architect the future of recovery, aiming to close a critical gap in patient care.

A national network is expanding its specialized centers, offering a new model of lifetime care to combat years of diagnostic delays and dismissed pain.

Fresh off a blockbuster IPO, SpyGlass Pharma heads to a key investor summit. Can its revolutionary long-acting drug platform transform chronic eye care?

Amid a volatile market, Ligand presents its sustainable growth blueprint, powered by royalties and partnerships, to top investors this March.

As a deadly superbug spreads, BioVersys's BV100 enters late-stage trials, backed by promising data and a novel scientific approach to combat resistance.

The biotech plans to separate its R&D pipeline from its booming royalty assets, creating two public companies and winning applause from Wall Street.

With record 2025 revenue and a dominant hold on the gene therapy market, Cryoport's strategic investments pave a path toward profitability.

The nation's leading aesthetic provider launches a Salmon DNA Facial, XTherma, and NAD+ injections, betting on the science of regenerative beauty.

The acquisition signals a major trend: investors are banking on professional skincare and the mature consumer. Here's what the deal means for the industry.

The D.C. transplant institute surpasses a historic milestone, pioneering new tech and giving thousands a second chance at life amid a national organ shortage.

A unique $4M award program aims to solve a critical funding gap, accelerating high-risk, high-reward cancer therapies from academic labs to patients.

Known for baked makeup, Laura Geller Beauty launches a cream palette, targeting women 40+ with a hydrating formula and a star-studded, age-positive campaign.

With a soaring stock and a breakthrough CAR-T therapy, Immix Biopharma is set to capture investor attention. What's behind the hype for its lead drug, NXC-201?

Daxor reports a transformative year with 45% revenue growth, a new FDA-cleared portable analyzer, and a full pivot to a high-growth medtech company.

As Akebia heads to a major conference, investors watch its Vafseo launch, new rare disease pipeline, and path to profitability. Here's what's at stake.

A new survey reveals a silent public health crisis as millions of Canadians face chronic sleep loss, with many admitting to driving while dangerously tired.

After a kidney trial setback, CalciMedica's lead drug Auxora shows strong promise for acute pancreatitis, but a tight cash runway looms over its future.